Evidence map›Paper›PMID 41220525›Full record

ArticleJMA journal2025

Granisetron as a Novel Treatment for Acute Food Protein-induced Enterocolitis Syndrome.

Kouhei Hagino, Marei Omori, Daisuke Harama, Kotaro Umezawa, Daichi Suzuki, Chisato Jimbo, Tomoki Yaguchi, Fumi Ishikawa, Seiko Hirai, Kenji Toyokuni and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JMA journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kouhei HaginoAllergy Center, National Center for Child Health and Development, Tokyo, Japan.
Marei OmoriAllergy Center, National Center for Child Health and Development, Tokyo, Japan.
Daisuke HaramaAllergy Center, National Center for Child Health and Development, Tokyo, Japan.
Kotaro UmezawaAllergy Center, National Center for Child Health and Development, Tokyo, Japan.
Daichi SuzukiAllergy Center, National Center for Child Health and Development, Tokyo, Japan.
Chisato JimboAllergy Center, National Center for Child Health and Development, Tokyo, Japan.
Tomoki YaguchiAllergy Center, National Center for Child Health and Development, Tokyo, Japan.
Fumi IshikawaAllergy Center, National Center for Child Health and Development, Tokyo, Japan.
Seiko HiraiAllergy Center, National Center for Child Health and Development, Tokyo, Japan.
Kenji ToyokuniAllergy Center, National Center for Child Health and Development, Tokyo, Japan.
Tatsuki FukuieAllergy Center, National Center for Child Health and Development, Tokyo, Japan.
Yukihiro OhyaAllergy Center, National Center for Child Health and Development, Tokyo, Japan.
Kiwako Yamamoto-HanadaAllergy Center, National Center for Child Health and Development, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute food protein-induced enterocolitis syndrome (FPIES) is a non-immunoglobulin E-mediated food allergy characterized by delayed-onset vomiting, which can lead to severe dehydration and shock. Ondansetron, a 5-hydroxytryptamine 3 receptor antagonist, is recommended for managing acute episodes, but granisetron, a similar antiemetic, lacks global approval for FPIES. Our case series aimed to evaluate the effectiveness and safety of intravenous granisetron in acute FPIES episodes. We report three cases of infants with acute FPIES triggered by egg yolk during oral food challenges. Each patient received intravenous granisetron after multiple vomiting episodes. Clinical outcomes, including cessation of vomiting and resumption of oral intake, were assessed. Vomiting ceased within an hour after granisetron administration in all cases, allowing successful oral rehydration. No adverse effects or recurrence of symptoms were observed, and all patients were discharged the following day. The clinical outcomes were comparable to those reported for ondansetron. Our findings suggest that intravenous granisetron is a safe and effective secondary therapy for acute FPIES reactions. Given the limited evidence on granisetron for FPIES, accumulating case reports is essential for guiding clinical trials and regulatory approval. Further comparative studies of granisetron and ondansetron are warranted.

Indexed as

food protein-induced enterocolitis syndromegranisetronoral food challenge test

Identifiers

PMID41220525
PMCPMC12598236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.